Nektar Therapeutics came into this earnings print trading like a high expectation growth story, with the stock up over the past month, only to see the shares slip about 4% on the immediate reaction. The tension is simple. Investors are paying a rich revenue multiple for a company that still reports modest revenue of just over US$10 million and a quarterly net loss above US$40 million.

The real headline is not the loss itself. It is the size of that loss against an already expensive P/S multiple and the reminder that Nektar Therapeutics remains firmly in cash burn mode while investors wait on its autoimmune pipeline.

Love the pipeline potential at Nektar Therapeutics but concerned about the ongoing cash burn and rich revenue multiple? You may want to use the list of solid balance sheet and fundamentals stocks (51 results) as a benchmark for stocks that pair growth stories with stronger balance sheets and fundamentals.

Q2 2026 Earnings Summary

• Total Revenue (Q2 2026 vs Q2 2025): US$10.13 million vs. US$11.18 million (decline of 9.4%)
• Net Loss (Q2 2026 vs Q2 2025): US$40.62 million vs. US$41.59 million (narrowed by 2.3%)
• Basic EPS (Q2 2026 vs Q2 2025): loss of US$1.23 per share vs. loss of US$2.95 per share (loss per share improved by 58.4%)
• Trailing 12 Month Net Loss (Q2 2026 TTM vs Q2 2025 TTM): US$157.13 million vs. US$122.27 million (loss widened by 28.5%)

Prefer clear visuals instead of parsing another dense earnings release for Nektar Therapeutics? See the full picture of the company, including a focused look at its financial health, in the interactive company report for Nektar Therapeutics.

Rezpegaldesleukin Bull Case: Pivotal Steps, Long Runway

Bulls argue that Nektar Therapeutics is turning rezpegaldesleukin into a broad autoimmune franchise with enough cash to see key trials through. Q2 confirms real progress on that story. The ZENITH AD Phase III program is now live with two global pivotal trials enrolling and a third study for treatment experienced patients expected by late September 2026. That matches the narrative of a product moving firmly into registrational development. Management also secured US$1.02b in cash and guided runway into Q3 2028, which covers the targeted mid 2028 AD Phase III readout and a planned 2029 BLA filing. Physician research from 151 high volume prescribers supports the idea that rezpegaldesleukin’s infrequent dosing and safety profile could fit across first, second and third line use. On the bullish milestones list, late stage execution and funding visibility both move forward.

Nektar Bear Case: Cash Burn, Concentration Risks Still Bite

Bears focus on heavy losses, a long catalyst timeline and reliance on a single late stage asset. Q2 numbers give that view some backing. Revenue remains modest at US$10.13 million and the quarterly net loss is US$40.62 million, with trailing 12 month losses at US$157.13 million. Management even raised R&D guidance to US$210 to 230 million and G&A to US$60 to 65 million. That supports concerns about ongoing cash burn despite the expanded cash balance. The story also remains concentrated in rezpegaldesleukin, with Phase III AD and planned AA programs and only early T1D and TNFR2 efforts behind it. Institutional ownership has fallen about 16 percentage points quarter on quarter and insider selling under 10b5 1 plans continues with no reported insider buying. The stock fell about 4% on the earnings reaction. All of this keeps execution and dilution worries very much alive.

Compare Nektar Therapeutics’ internal progress on rezpegaldesleukin with the share price reaction and consider whether Wall Street expects this cash burn and single asset focus to pay off over time by checking the consensus price target analysis for Nektar Therapeutics.

Stay Ahead Of Your Next Move

If Nektar Therapeutics’ mix of rezpegaldesleukin progress, cash burn and a rich revenue multiple has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry point. After you decide to build a position, use the Portfolio Command Center to cut through market noise and focus on the key updates that actually matter to your holdings. For a longer term view, tap into crowd insights and sentiment through the Community so you can see how other investors are reacting to new data. By spotting potential catalysts and risks early, you give yourself a better chance to act before the wider market catches on.

Seeking Fresh Alternatives Beyond Nektar?

Some stocks are already building quiet breakout momentum while others risk getting caught before the story is fully priced in. Scan these fresh ideas before the crowd and act now.

• Spot resilient cash generators that keep flying through volatility by scanning the curated list of solid balance sheet and fundamentals stocks (51 results) while balance sheet strength still sits under the radar for now.
• Chase upside in income opportunities that many overlook by running through the hand picked 10 dividend fortresses while yields and coverage ratios still look compelling.
• Track accelerating automation momentum with a focused sweep of 37 robotics and automation stocks before these operators move from quiet progress to fully priced growth stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.